American College of Cardiology Urges Heart Attack, Stroke Patients to Seek Medical Help

Through its CardioSmart patient initiative, the American College of Cardiology has issued guidance to encourage patients experiencing a heart attack or stroke to call 911.  While hospitals across the United States are experiencing an influx of COVID-19 patients, clinicians are reportedly seeing fewer patients going to emergency rooms for heart attack or stroke. Experts worry that patients who need critical care are delaying their treatment over concerns about the novel coronavirus.

“Due to fears of contracting COVID-19 or taking up space in hospitals, patients experiencing a heart attack or stroke are delaying their essential care, causing a new public health crisis,” said Martha Gulati, MD, FACC, editor-in-chief of CardioSmart.org. “Hospitals and catheterization labs are still treating heart attack and stroke, not just COVID-19, and are taking the utmost precautions to ensure that the novel coronavirus not be spread. The faster a patient is treated, the higher the outcome of survival and lower the risk for complications. No patient should delay their care.”

A new CardioSmart infographic, “Coronavirus and Your Heart: Don’t Ignore Heart Symptoms,” encourages patients to pay close attention to heart attack or stroke symptoms, particularly if they have a pre-existing heart condition, and call 911 immediately if they believe they’re having a heart attack or stroke. The infographic details common heart attack and stroke symptoms and ensures hospitals are taking steps to protect them from COVID-19. The infographic also encourages patients to continue routine heart care to ensure they stay healthy, which may be accomplished through telehealth (remote or virtual visit) or a phone call with their clinician.

“We encourage clinicians to widely distribute these tools to their patients. Make sure that patients know when telehealth is an appropriate option, and when they should call 911 instead,” Gulati said. “Clinicians should work with patients to ensure medication adherence, and always continue to advocate for heart-healthy measures that can be taken even in times of self-isolation and social distancing.”

CardioSmart serves as the ACC’s patient engagement initiative. Reviewed by experts in the CardioSmart COVID-19 Response Work Group, the new infographic joins the full collection of ACC COVID-19 resources, including clinical bulletins, journal articles, patient summaries and more. For more information about how COVID-19 affects patients with pre-existing heart conditions, and to download the full infographic, visit the CardioSmart COVID-19 Hub.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.